dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mirallas Viñas, Oriol |
dc.contributor.author | Pardo Aranda, Nuria |
dc.contributor.author | Aubanell, Anton |
dc.contributor.author | Salcedo Allende, Maria Teresa |
dc.contributor.author | Callejo Perez, Ana |
dc.contributor.author | Iranzo Gómez, Patricia |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Bosch Schips, Marc |
dc.date.accessioned | 2022-09-05T11:41:30Z |
dc.date.available | 2022-09-05T11:41:30Z |
dc.date.issued | 2022-03 |
dc.identifier.citation | Mirallas O, Bosch-Schips M, Pardo N, Aubanell A, Salcedo-Allende MT, Callejo A, et al. Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. Front Oncol. 2022 Mar;12:837630. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/8026 |
dc.description | Metastatic hepatic rupture; Non-small cell lung carcinoma; Tyrosine kinase inhibitor |
dc.description.abstract | Hepatic rupture is a rare complication of solid tumor malignancies, notably in lung adenocarcinomas, and carries an extremely poor overall prognosis. Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma predict benefit with tyrosine kinase inhibitors (TKIs). This case report describes a female patient who presented with a metastatic hepatic rupture and was subsequently diagnosed with EGFR-mutated lung adenocarcinoma. The tumor had an impressive response to TKI inhibitor treatment, reversing her extremely poor, short-term prognosis. We believe this unique case sheds light on the treatment management of hepatic ruptures and supports the high response rate seen with TKIs in EGFR-mutated lung cancers, regardless of the patient’s performance status. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Adenocarcinoma - Tractament |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Proteïnes quinases - Inhibidors |
dc.subject.mesh | Adenocarcinoma of Lung |
dc.subject.mesh | /therapy |
dc.subject.mesh | Protein Kinase Inhibitors |
dc.title | Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2022.837630 |
dc.subject.decs | adenocarcinoma de pulmón |
dc.subject.decs | /terapia |
dc.subject.decs | inhibidores de proteínas cinasas |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2022.837630 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mirallas O, Pardo N, Callejo A, Iranzo P, Tabernero J, Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bosch-Schips M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salcedo-Allende MT] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 35433405 |
dc.identifier.wos | 000788209600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |